Search Results
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered
More news about: Ascletis Pharma Inc.
Sep 08, 2026, 06:10 ET 歌禮宣布在美國啟動口服胰澱素受體激動劑多肽ASC36治療肥胖症的I期研究
點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Sep 07, 2026, 00:15 ET Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered
More news about: Ascletis Pharma Inc.
Sep 07, 2026, 00:15 ET 歌禮宣佈獲納入滬港通及深港通計劃項下的港股通名單
點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Aug 30, 2026, 06:15 ET Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered
More news about: Ascletis Pharma Inc.
Aug 30, 2026, 06:15 ET 歌禮宣布每日一次口服小分子GLP-1受體激動劑ASC30用於長期體重管理的全球III期臨床項目完成首例受試者給藥
點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Aug 26, 2026, 06:37 ET Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
costs.Pre-clinical Candidate (PCC) Nominations:In January, the Company announced the nomination of ISM0676, a novel oral small molecule GIPR antagonist. It achieved 31.3% weight loss in preclinical models, demonstrating best-in-class potential and providing an innovative small molecule solution
More news about: Insilico Medicine
Aug 10, 2026, 07:00 ET Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered
More news about: Ascletis Pharma Inc.
Aug 10, 2026, 07:00 ET 歌禮宣布在美國啟動兩項治療肥胖症的I期研究：胰澱素受體激動劑多肽月注射劑ASC36、ASC36和GLP-1R/GIPR激動劑多肽ASC35的復方月注射劑ASC36_35FDC
PR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). MariTide's long-acting design supports starting with monthly dosing, and staying on MariTide with as few as 4 or 6 doses per year.MARITIME-1,
More news about: Amgen
Aug 03, 2026, 06:55 ET 歌禮宣佈其GLP-1口服小分子ASC30啟動全球III期臨床研究，並公佈其同類首創口服小分子GLP-1/GIP/胰澱素固定劑量復方制劑的積極臨床前數據
III期GLP-1R/GIPRASC30_48FDC
More news about: 歌禮製藥有限公司
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35 FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered
More news about: Ascletis Pharma Inc.
Jul 27, 2026, 06:10 ET Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist,
More news about: Ascletis Pharma Inc.
Jul 27, 2026, 06:10 ET 歌禮宣布每月一次皮下注射GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37在飲食誘導肥胖小鼠模型中展現出優越的減重效果
香港2026年7月27日 /美通社/ -- 歌禮制藥有限公司（香港聯交所代碼：1672，簡稱「歌禮」）宣布，新一代GLP-1R/GIPR/GCGR[1]三靶點激動劑多肽ASC37，在飲食誘導肥胖（DIO）小鼠模型中展現出了優於替爾泊肽的減重效果。在DIO小鼠中，以1 nmol/kg的相同劑量給藥11天後，ASC37的減重效果較替爾泊肽相對提升88%，且差異具有統計學顯著性（表1）。此外，在DIO小鼠中，ASC37實現了高達41.5%的體重下降（表1），且呈劑量依賴性。
More news about: 歌禮製藥有限公司
Jul 22, 2026, 20:10 ET Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist,
More news about: Ascletis Pharma Inc.
Jul 22, 2026, 20:10 ET 歌禮宣佈將在第62屆歐洲糖尿病研究協會（EASD）年會上以口頭討論形式匯報ASC36_35 FDC減重效果優於eloralintide聯合tirzepatide的臨床前數據
靶點激動劑，在DIO大鼠中顯示出優於eloralintide聯合tirzepatide的減重效果（Co-formulation of ASC36 and ASC35, once-monthly amylin receptor agonist and GLP-1R/GIPR agonist, demonstrated superior weight loss to eloralintide/tirzepatide combo in DIO rats）簡短口頭討論專場會議F簡短口頭討論專場：SO
More news about: 歌禮製藥有限公司
Jul 15, 2026, 06:00 ET Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
first-in-class oral small molecule GIPR agonist.- ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM) and is a selective agonist for GIPR without activity for GLP-1R and
More news about: Ascletis Pharma Inc.
Jul 15, 2026, 06:00 ET 歌禮選定同類首創口服小分子GIPR激動劑ASC48和口服小分子GLP-1R激動劑ASC30的固定劑量復方制劑進行臨床開發
Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款在研小分子GLP-1R激動劑，既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法，用於長期體重管理；ASC36，一款胰澱素受體激動劑多肽，ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，ASC39，一款類似eloralintide、對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，ASC30_39 FDC，ASC30（GLP-1RA）與ASC39（胰澱素受體激動劑）的固定劑量復方制劑（FDC），和ASC30_48
More news about: 歌禮製藥有限公司
Jul 08, 2026, 20:30 ET Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
preclinical candidate compounds (PCCs) in H1 2026 by combining its generative AI platform with automated laboratory workflows. These include ISM0676, a GIPR antagonist demonstrating up to 31.3% weight loss in preclinical models; ISM5059, an NLRP3 inhibitor for systemic inflammatory diseases; ISM6166, a pan-KRAS
More news about: Insilico Medicine
Jul 05, 2026, 21:10 ET Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist,
More news about: Ascletis Pharma Inc.
Jul 05, 2026, 20:10 ET 歌禮向美國FDA遞交兩項治療肥胖症的IND申請：多肽胰澱素受體激動劑月注射劑ASC36以及ASC36聯合多肽GLP-1R/GIPR激動劑ASC35的ASC36_35復方月注射劑
Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款在研小分子GLP-1R激動劑，既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法，用於長期體重管理；ASC36，一款胰澱素受體激動劑多肽，ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，ASC39，一款類似eloralintide、對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，和ASC30_39 FDC，ASC30（GLP-1RA）與ASC39（胰澱素受體激動劑）的固定劑量復方制劑（FDC），用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。
More news about: 歌禮製藥有限公司
Jun 23, 2026, 06:10 ET Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist,
More news about: Ascletis Pharma Inc.
Jun 23, 2026, 06:10 ET 歌禮宣佈其每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽ASC35治療肥胖症的I期研究IND獲美國FDA批准
Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款在研小分子GLP-1R激動劑，既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法，用於長期體重管理；ASC36，一款胰澱素受體激動劑多肽，ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，ASC39，一款類似eloralintide、對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，和ASC30_39 FDC，ASC30（GLP-1RA）與ASC39（胰澱素受體激動劑）的固定劑量復方制劑（FDC），用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Jun 07, 2026, 20:10 ET 歌禮ASC30臨床數據與ASC37、ASC39令人振奮的臨床前結果於美國糖尿病協會（ADA）2026年度科學會議齊亮相，夯實差異化肥胖管線
3. 口服GLP-1R/GIPR/GCGR三靶點激動劑多肽：ASC37ASC37是一款利用歌禮專有的口服多肽遞送增強技術（POTENT）開發而成的口服GLP-1R/GIPR/GCGR三靶點激動劑多肽。通過抑制酶降解並增加胃腸道通透性，POTENT能夠將多肽的口服生物利用度從<1%提高至約3%–5%。在非人靈長類動物中，採用歌禮POTENT制劑的司美格魯肽的絕對口服生物利用度是採用其商業化SNAC（N-8-(2-羥基苯甲酰胺基)辛酸鈉）制劑的司美格魯肽的3倍；而採用歌禮POTENT制劑的替爾泊肽的絕對口服生物利用度是採用SNAC制劑的替爾泊肽的9倍。
More news about: 歌禮製藥有限公司
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
maintenance doses of 20 mg, 40 mg, and 60 mg, with dose titration periods of up to 20 weeks.3. Oral GLP-1R/GIPR/GCGR Triple Agonist Peptide: ASC37ASC37 is an oral GLP-1R/GIPR/GCGR triple agonist peptide developed using Ascletis' proprietary Peptide Oral Transport ENhancement Technology
More news about: Ascletis Pharma Inc.